Charles Schwab
NGNE icon

Charles Schwab’s Neurogene NGNE Stock Holding History

Charles Schwab’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.03M Buy
32,742
+2,684
+9% +$73.9K ﹤0.01% 3000
2026
Q1 		$606K Buy
30,058
+99
+0.3% +$1.92K ﹤0.01% 3044
2025
Q4 		$617K Hold
29,959
– – ﹤0.01% 3094
2025
Q3 		$519K Hold
29,959
– – ﹤0.01% 3163
2025
Q2 		$448K Sell
29,959
-4,010
-12% -$62.9K ﹤0.01% 3174
2025
Q1 		$398K Buy
33,969
+3,652
+12% +$63.4K ﹤0.01% 3139
2024
Q4 		$693K Hold
30,317
– – ﹤0.01% 3039
2024
Q3 		$1.27M Buy
30,317
+741
+3% +$28.7K ﹤0.01% 2845
2024
Q2 		$1.08M Buy
29,576
+24,337
+465% +$858K ﹤0.01% 2911
2024
Q1 		$267K Buy
+5,239
New +$175K ﹤0.01% 3198
2022
Q2 		– Sell
-4,430
Closed -$167K – 3610
2022
Q1 		$167K Hold
4,430
– – ﹤0.01% 3333
2021
Q4 		$428K Hold
4,430
– – ﹤0.01% 3193
2021
Q3 		$641K Hold
4,430
– – ﹤0.01% 3057
2021
Q2 		$818K Buy
4,430
+302
+7% +$66.8K ﹤0.01% 2997
2021
Q1 		$1.02M Buy
4,128
+292
+8% +$74.6K ﹤0.01% 2856
2020
Q4 		$1.08M Sell
3,836
-7
-0.2% -$1.71K ﹤0.01% 2749
2020
Q3 		$923K Buy
3,843
+145
+4% +$35.1K ﹤0.01% 2693
2020
Q2 		$1.23M Buy
3,698
+2,995
+426% +$781K ﹤0.01% 2566
2020
Q1 		$160K Hold
703
– – ﹤0.01% 3049
2019
Q4 		$174K Buy
+703
New +$70K ﹤0.01% 3056
2019
Q3 		– Sell
-841
Closed -$40K – 3187
2019
Q2 		$40K Hold
841
– – ﹤0.01% 3164
2019
Q1 		$46K Buy
+841
New +$42.5K ﹤0.01% 3148

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Charles Schwab's NGNE Position: Q2 2026 in Review

Charles Schwab increased its Neurogene (NGNE) stake by 8.9% in Q2 2026, buying an estimated $73.9K and bringing the position to 32,742 shares worth $1.03M. The position accounts for ﹤0.01% of the portfolio, ranked #3000.

Charles Schwab first reported a position in NGNE in Q1 2019 and has held it in 22 quarters since. The position peaked at $1.27M in Q3 2024. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Charles Schwab held 32,742 shares of Neurogene worth $1.03M as of Q2 2026.
  • Charles Schwab bought 2,684 Neurogene shares in Q2 2026, an estimated $73.9K.
  • Neurogene made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3000 holding.
  • Charles Schwab first reported a position in Neurogene in Q1 2019 and has held it in 22 quarters since.
  • Charles Schwab's Neurogene position peaked at $1.27M in Q3 2024.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.